International Faculty

José Maria de La Torre Hernández, MD, Phd

Interventional cardiologist
University Hospital Marquês de Valdecilla, Santander, Spain

Medical degree in 1991 and Doctorate PhD in 2001.

  • Cardiology specialist in national program (1993-1997), Cardiology research fellow in Mount Sinai Medical Center, NY (1996) and Interventional Cardiology fellowship (1998-2001).
  • Head of Cardiology Dpt. in Hospital Universitario Marques de Valdecilla, Santander, Spain.
  • Director of Cardiovascular research group in HUMV-IDIVAL.
  • Associate professor in Medical School, University of Cantabria.
  • Vice-president (elected) of the Spanish Society of Cardiology since 2021.
  • Patron and research coordinator in EPIC Foundation-Association.
  • Fellow of the European Society of Cardiology. Elected member of the steering committee of the Spanish Interventional. Cardiology Working Group for 2009-2012.
  • Visiting scientist in the Biomedical Engineering Center in the Institute of Medical Engineering and Science at MIT, US (2016-2017).
  • Associate director of TCT (2017) and regular faculty in international meetings (PCR, ESC, ACC and TCT).

Author in 204 manuscripts for peer-review journals, but also from the perspective of the editorial duties, currently serving as:
- Founder and Editor in Chief of REC: Interventional Cardiology,
- Editorial consultant in JACC Interventions,
- Section editor in Eurointervention
- Member of the editorial committee of Revista Española de Cardiologia (REC) among others.

Devoted to multicenter collaborative and nation-wide registries and trials since 2004, starting with the leading role for the LITRO and ESTROFA study groups and now as scientific coordinator in EPIC foundation conducting up to 15 multicenter studies in last 5 years. Participation in over 75 clinical trials. Main research topics have been mostly focused on drug-eluting stents, intravascular imaging, left main PCI, but also other areas such as antithrombotic therapies after PCI, management of elderly population with coronary artery disease and TAVR.